$JAZZ
Jazz Pharmaceuticals PLC

2023 Q4 Form 10-Q Financial Statement

#000123252423000052 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $1.012B $972.1M
YoY Change 4.1% 3.35%
Cost Of Revenue $107.2M $102.2M
YoY Change -35.92% -23.54%
Gross Profit $904.7M $870.0M
YoY Change 12.42% 7.81%
Gross Profit Margin 89.4% 89.49%
Selling, General & Admin $396.0M $308.3M
YoY Change 3.35% -13.99%
% of Gross Profit 43.78% 35.44%
Research & Development $234.6M $234.4M
YoY Change -57.15% 57.45%
% of Gross Profit 25.93% 26.94%
Depreciation & Amortization $159.2M $162.6M
YoY Change 10.0% 9.26%
% of Gross Profit 17.6% 18.69%
Operating Expenses $782.2M $542.7M
YoY Change -26.77% 6.97%
Operating Profit $122.5M $172.4M
YoY Change -146.51% 596.17%
Interest Expense -$60.97M -$71.50M
YoY Change -20.41% -10.9%
% of Operating Profit -49.77% -41.47%
Other Income/Expense, Net
YoY Change
Pretax Income $61.53M $99.52M
YoY Change -118.1% -265.5%
Income Tax -$33.09M -$47.20M
% Of Pretax Income -53.78% -47.43%
Net Earnings $94.15M $146.8M
YoY Change -139.11% -847.25%
Net Earnings / Revenue 9.3% 15.1%
Basic Earnings Per Share $2.33
Diluted Earnings Per Share $1.35 $2.14
COMMON SHARES
Basic Shares Outstanding 62.96M shares 63.13M shares
Diluted Shares Outstanding 71.29M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.626B $1.586B
YoY Change 84.5% 76.35%
Cash & Equivalents $1.506B $1.336B
Short-Term Investments $120.0M $810.0M
Other Short-Term Assets $320.8M $310.4M
YoY Change 20.07% 24.15%
Inventory $597.0M $611.8M
Prepaid Expenses $185.5M $110.0M
Receivables $705.8M $627.8M
Other Receivables $149.3M $101.0M
Total Short-Term Assets $3.435B $3.246B
YoY Change 31.82% 26.22%
LONG-TERM ASSETS
Property, Plant & Equipment $235.0M $288.0M
YoY Change -22.03% -0.71%
Goodwill $1.753B $1.705B
YoY Change 3.57% 7.08%
Intangibles $5.418B $5.418B
YoY Change -6.5% -2.74%
Long-Term Investments
YoY Change
Other Assets $67.46M $76.08M
YoY Change 22.35% 116.43%
Total Long-Term Assets $7.958B $7.958B
YoY Change -3.3% 1.86%
TOTAL ASSETS
Total Short-Term Assets $3.435B $3.246B
Total Long-Term Assets $7.958B $7.958B
Total Assets $11.39B $11.20B
YoY Change 5.15% 7.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $102.8M $109.9M
YoY Change 13.21% 7.43%
Accrued Expenses $793.9M $769.9M
YoY Change -1.16% 15.19%
Deferred Revenue $0.00 $4.000K
YoY Change -100.0% -99.54%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $605.0M $604.5M
YoY Change 1851.46% 1850.02%
Total Short-Term Liabilities $1.537B $1.573B
YoY Change 64.67% 93.53%
LONG-TERM LIABILITIES
Long-Term Debt $5.108B $5.111B
YoY Change -10.28% -10.27%
Other Long-Term Liabilities $104.8M $127.5M
YoY Change -1.93% 2.86%
Total Long-Term Liabilities $5.213B $5.238B
YoY Change -10.13% -9.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.537B $1.573B
Total Long-Term Liabilities $5.213B $5.238B
Total Liabilities $6.749B $6.812B
YoY Change 0.24% 2.7%
SHAREHOLDERS EQUITY
Retained Earnings $878.7M $884.3M
YoY Change 19.78% -9.24%
Common Stock $3.700B $3.640B
YoY Change 6.41% 7.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.737B $3.489B
YoY Change
Total Liabilities & Shareholders Equity $11.39B $11.20B
YoY Change 5.15% 7.89%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $94.15M $146.8M
YoY Change -139.11% -847.25%
Depreciation, Depletion And Amortization $159.2M $162.6M
YoY Change 10.0% 9.26%
Cash From Operating Activities $167.3M $307.2M
YoY Change -51.07% -26.51%
INVESTING ACTIVITIES
Capital Expenditures $28.10M $4.300M
YoY Change -92.69% -12.28%
Acquisitions
YoY Change
Other Investing Activities $129.9M -$170.0M
YoY Change 116.5% 56566.67%
Cash From Investing Activities $101.8M -$174.3M
YoY Change -131.38% -3887.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -100.3M -78.40M
YoY Change -611.87% -72.88%
NET CHANGE
Cash From Operating Activities 167.3M 307.2M
Cash From Investing Activities 101.8M -174.3M
Cash From Financing Activities -100.3M -78.40M
Net Change In Cash 168.8M 54.50M
YoY Change 353.98% -59.19%
FREE CASH FLOW
Cash From Operating Activities $167.3M $307.2M
Capital Expenditures $28.10M $4.300M
Free Cash Flow $139.2M $302.9M
YoY Change -428.33% -26.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001232524
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
Jazz Pharmaceuticals plc
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
463000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1573329000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
933193000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5110757000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5693341000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61892000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
71838000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
841234000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
944337000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
127480000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
106812000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q3 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000 usd
CY2022Q4 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000 usd
CY2023Q3 jazz Capital Redemption Reserve
CapitalRedemptionReserve
473000 usd
CY2022Q4 jazz Capital Redemption Reserve
CapitalRedemptionReserve
472000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3639940000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3477124000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1035399000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1125509000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
884298000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
733586000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3489373000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3085734000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11204065000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10835255000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
947071000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1033764000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
633050000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
417898000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
456731000 usd
dei Amendment Flag
AmendmentFlag
false
CY2021 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member
CY2023Q3 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2822269000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2687251000 usd
jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
328334000 usd
jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
373153000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
461782000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1000000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
69148000 usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
133648000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
133648000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
799748000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
915889000 usd
us-gaap Costs And Expenses
CostsAndExpenses
2366186000 usd
us-gaap Costs And Expenses
CostsAndExpenses
2489393000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
172392000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
24763000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
456083000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
197858000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-71497000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-80244000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-219114000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-214117000 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1377000 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4649000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-566000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-16532000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
99518000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-60130000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
236403000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-32791000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-47176000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-43027000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-86823000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-58603000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
126000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2545000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2548000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-9148000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
146820000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19648000 usd
us-gaap Net Income Loss
NetIncomeLoss
320678000 usd
us-gaap Net Income Loss
NetIncomeLoss
16664000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.33
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.14
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63114000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62785000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63532000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62365000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71293000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62785000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72866000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63388000 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
146820000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19648000 usd
us-gaap Net Income Loss
NetIncomeLoss
320678000 usd
us-gaap Net Income Loss
NetIncomeLoss
16664000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-170826000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-511617000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
82952000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1217414000 usd
CY2023Q3 jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationTax
0 usd
CY2022Q3 jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationTax
0 usd
jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationTax
0 usd
jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationTax
-43000 usd
CY2023Q3 jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationAndTax
0 usd
CY2022Q3 jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationAndTax
0 usd
jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationAndTax
0 usd
jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationAndTax
128000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
1176000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
3063000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
3539000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
9218000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
428000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
684000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
1289000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
2060000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-168576000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-511617000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
90110000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1217286000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21756000 usd
jazz Inventory Step Up Value Adjustment
InventoryStepUpValueAdjustment
203189000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-531265000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
410788000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1200622000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3085734000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21228000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
43266000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56646000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
145279000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
69420000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3335041000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2003000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8863000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4188000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
61705000 usd
CY2023Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
95594000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
113407000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
104438000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3525675000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5512000 usd
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1884000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56197000 usd
CY2023Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
74371000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-168576000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
146820000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3489373000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3965191000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21729000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
33776000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50106000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190360000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1647000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
3608487000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16640000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8234000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6289000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
54407000 usd
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
54000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-515309000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
34665000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3200781000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21260000 usd
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2567000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56985000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-511617000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19648000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2745194000 usd
us-gaap Net Income Loss
NetIncomeLoss
320678000 usd
us-gaap Net Income Loss
NetIncomeLoss
16664000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
456731000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
461782000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
173900000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
160438000 usd
jazz Inventory Step Up Value Adjustment
InventoryStepUpValueAdjustment
119094000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-54262000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
26352000 usd
us-gaap Depreciation
Depreciation
22764000 usd
us-gaap Depreciation
Depreciation
22958000 usd
jazz Noncash Interest Expense
NoncashInterestExpense
16255000 usd
jazz Noncash Interest Expense
NoncashInterestExpense
32002000 usd
jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
7732000 usd
jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
13066000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1000000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
69148000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
133648000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-39258000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-224317000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-146874000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-23581000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
43868000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12016000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
50458000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
37327000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23801000 usd
jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-14423000 usd
jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-10672000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
20881000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4006000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
17705000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4188000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-76261000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
17864000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
61159000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-172000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-459000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1570000 usd
jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-13855000 usd
jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-12139000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
20500000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
6767000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
924668000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
930006000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
20000000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 usd
jazz Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination
PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination
1000000 usd
jazz Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination
PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination
69148000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13860000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19668000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
270000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
61036000 usd
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 usd
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
53000000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-264860000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-121852000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
37606000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
67863000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
23250000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
574264000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
49338000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
42632000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
169966000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
54000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
454208000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
881482000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
591448000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</span></div>We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding.We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1585690000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1585690000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1335690000 usd
CY2023Q3 us-gaap Investments
Investments
250000000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
881482000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
881482000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
881482000 usd
CY2022Q4 us-gaap Investments
Investments
0 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
19200000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
44400000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3500000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
4400000 usd
CY2023Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
5500000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
5500000 usd
us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
5100000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
20786000 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
457877000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
517670000 usd
CY2023Q3 us-gaap Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement
DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
10908000 usd
CY2022Q4 us-gaap Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement
DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
17356000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
25028000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
128922000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
175605000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
611827000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
714061000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1692662000 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
12658000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
1705320000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7591748000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2173888000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5417860000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7506287000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1711850000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5794437000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
150595000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
602379000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
602379000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
602379000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
602379000 usd
CY2023Q3 jazz Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
2857749000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5417860000 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
22200000 usd
CY2023Q3 jazz Sales Return Reserve Current
SalesReturnReserveCurrent
20150000 usd
CY2022Q4 jazz Sales Return Reserve Current
SalesReturnReserveCurrent
26164000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
18507000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
22278000 usd
CY2023Q3 jazz Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
16722000 usd
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
347295000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
335697000 usd
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
124819000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
107647000 usd
CY2023Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
222476000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
228050000 usd
CY2023Q3 jazz Deferred Tax Intercompany Profit Current
DeferredTaxIntercompanyProfitCurrent
209009000 usd
CY2022Q4 jazz Deferred Tax Intercompany Profit Current
DeferredTaxIntercompanyProfitCurrent
176057000 usd
CY2023Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
101395000 usd
CY2022Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
91135000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
310404000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
267192000 usd
CY2022Q4 jazz Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
313176000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
143243000 usd
CY2023Q3 jazz Accrued Facilities Expenses Current
AccruedFacilitiesExpensesCurrent
52006000 usd
CY2022Q4 jazz Accrued Facilities Expenses Current
AccruedFacilitiesExpensesCurrent
25864000 usd
CY2022Q4 jazz Accrued Clinical Trial Liability Current
AccruedClinicalTrialLiabilityCurrent
31338000 usd
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
28336000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
57347000 usd
CY2023Q3 jazz Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
23530000 usd
CY2022Q4 jazz Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
33205000 usd
CY2022Q4 jazz Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
15938000 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
15964000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2023Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
14573000 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
18553000 usd
CY2023Q3 jazz Accrued Inventory Related Liabilities Current
AccruedInventoryRelatedLiabilitiesCurrent
10746000 usd
CY2022Q4 jazz Accrued Inventory Related Liabilities Current
AccruedInventoryRelatedLiabilitiesCurrent
8565000 usd
CY2023Q3 jazz Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
5167000 usd
CY2022Q4 jazz Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
3298000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
68672000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
803255000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
5715264000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
5724341000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
604507000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
31000000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5110757000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5693341000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
7750000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
606000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
31000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1031000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
31000000 usd
CY2023Q3 jazz Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
4098500000 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5805250000 usd
CY2021Q2 jazz Infringed Patents Suit Other Party Counterclaim Number Of Patents Requested To Be Delisted
InfringedPatentsSuitOtherPartyCounterclaimNumberOfPatentsRequestedToBeDelisted
1 patent
us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
92170000 usd
us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
2060000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
90110000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
146820000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19648000 usd
us-gaap Net Income Loss
NetIncomeLoss
320678000 usd
us-gaap Net Income Loss
NetIncomeLoss
16664000 usd
CY2023Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
5912000 usd
CY2022Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
19951000 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
152732000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19648000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
340629000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
16664000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63114000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62785000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63532000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62365000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
7560000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8549000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
619000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
785000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1023000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71293000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62785000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72866000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63388000 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.33
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.14
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
972140000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
940652000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2822269000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2687251000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
972140000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
940652000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2822269000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2687251000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56115000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56681000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
173900000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
160438000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
9792000 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
10715000 usd
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
29533000 usd
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
30632000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
46323000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
45966000 usd
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
144367000 usd
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
129806000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-47200000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-86800000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-43000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-58600000 usd
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.474 rate
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.367 rate
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.716 rate
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.787 rate
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
jazz-20230930_cal.xml Edgar Link unprocessable
0001232524-23-000052-index-headers.html Edgar Link pending
0001232524-23-000052-index.html Edgar Link pending
0001232524-23-000052.txt Edgar Link pending
0001232524-23-000052-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jazz-20230930.htm Edgar Link pending
jazz-20230930.xsd Edgar Link pending
jazzq32023ex311.htm Edgar Link pending
jazzq32023ex312.htm Edgar Link pending
jazzq32023ex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
jazz-20230930_def.xml Edgar Link unprocessable
jazz-20230930_lab.xml Edgar Link unprocessable
jazz-20230930_pre.xml Edgar Link unprocessable
jazz-20230930_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable